Rosario Pivonello

Summary

Country: Italy

Publications

  1. ncbi request reprint Impairment of bone status in patients with central diabetes insipidus
    R Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 83:2275-80. 1998
  2. ncbi request reprint Dopamine receptor expression and function in corticotroph ectopic tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:65-9. 2007
  3. ncbi request reprint The metabolic syndrome and cardiovascular risk in Cushing's syndrome
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, Naples 80131, Italy
    Endocrinol Metab Clin North Am 34:327-39, viii. 2005
  4. ncbi request reprint Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors
    R Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:82-8. 2003
  5. ncbi request reprint Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:4493-502. 2004
  6. ncbi request reprint Dopamine receptor expression and function in corticotroph pituitary tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:2452-62. 2004
  7. ncbi request reprint Cushing's syndrome: aftermath of the cure
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Arq Bras Endocrinol Metabol 51:1381-91. 2007
  8. doi request reprint The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery
    Rosario Pivonello
    Department of Molecular and Clinical, Endocrinology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:223-30. 2009
  9. ncbi request reprint Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:1674-83. 2004
  10. doi request reprint Cushing's Syndrome
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy
    Endocrinol Metab Clin North Am 37:135-49, ix. 2008

Detail Information

Publications120 found, 100 shown here

  1. ncbi request reprint Impairment of bone status in patients with central diabetes insipidus
    R Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 83:2275-80. 1998
    ..These findings suggest that, in patients with central diabetes insipidus, bone status analysis is mandatory; and a bone-loss preventing treatment might be beneficial...
  2. ncbi request reprint Dopamine receptor expression and function in corticotroph ectopic tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:65-9. 2007
    ..Dopamine receptor (DR) expression and dopamine agonist (DA) effectiveness have never been demonstrated in neuroendocrine tumors associated with ectopic ACTH syndrome (EAS)...
  3. ncbi request reprint The metabolic syndrome and cardiovascular risk in Cushing's syndrome
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, Naples 80131, Italy
    Endocrinol Metab Clin North Am 34:327-39, viii. 2005
    ..Considering the many patients subjected to corticosteroid treatment, this could be of great clinical relevance and should be investigated thoroughly...
  4. ncbi request reprint Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors
    R Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:82-8. 2003
  5. ncbi request reprint Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:4493-502. 2004
    ....
  6. ncbi request reprint Dopamine receptor expression and function in corticotroph pituitary tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:2452-62. 2004
    ..The effectiveness of cabergoline in normalizing cortisol secretion in 40% of cases supports its therapeutic use in the management of Cushing's disease...
  7. ncbi request reprint Cushing's syndrome: aftermath of the cure
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Arq Bras Endocrinol Metabol 51:1381-91. 2007
    ..The totality of these complications persisting or occurring after successful treatment contribute to the impairment of quality of life registered in patients with CS after disease cure...
  8. doi request reprint The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery
    Rosario Pivonello
    Department of Molecular and Clinical, Endocrinology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:223-30. 2009
    ..The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated...
  9. ncbi request reprint Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:1674-83. 2004
    ..In conclusion, this study demonstrates D(2) receptor expression and function in nearly 70% of cases, suggesting a role of this drug in the treatment schedule of clinically nonfunctioning pituitary tumors...
  10. doi request reprint Cushing's Syndrome
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy
    Endocrinol Metab Clin North Am 37:135-49, ix. 2008
    ..The prognosis of the disease is mainly affected by the difficulties in the diagnosis and treatment of the disease, which remain a considerable challenge...
  11. doi request reprint Pathophysiology of diabetes mellitus in Cushing's syndrome
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Neuroendocrinology 92:77-81. 2010
    ..This phenomenon is probably responsible for the passage from an impairment of glucose tolerance to an overt diabetes mellitus in susceptible patients with Cushing's syndrome...
  12. ncbi request reprint Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
    J Clin Endocrinol Metab 83:2777-80. 1998
    ..In conclusion, the medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function...
  13. ncbi request reprint Growth-hormone and prolactin excess
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Lancet 352:1455-61. 1998
    ..Moreover, the improvement in the management of acromegaly has enabled the reversal, at least partly, of cardiomyopathy and sleep apnoea, two important risk factors for morbidity and mortality in these patients...
  14. ncbi request reprint Treatment of prolactinomas
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Ann Med 30:452-9. 1998
    ..Pharmacotherapy with dopamine (DA) agonists is an appropriate first-line treatment for both micro- and macroprolactinomas. Surgery should be recommended for those patients who are severely intolerant of or resistant to DA agonists...
  15. ncbi request reprint Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 84:17-23. 1999
    ..These data suggest that prolonged suppression of circulating GH and IGF-I levels could normalize cardiac performance and probably reverse the poor prognosis for cardiovascular disease in acromegaly...
  16. ncbi request reprint Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration
    R Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 25:932-7. 2002
    ..In addition, replacement treatment with DDAVP normalized CRH-induced but not baseline ACTH and F secretion...
  17. ncbi request reprint Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 88:1629-36. 2003
    ..Conversely, autoimmunity probably represents an epiphenomenon in patients with nonidiopathic CDI...
  18. ncbi request reprint Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance
    Rosario Pivonello
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 92:476-82. 2007
    ..The aim of the current study was to evaluate the effect of short-term (6 months) and long-term (18 months) treatment with pegvisomant on cardiac structure and performance in patients with acromegaly...
  19. ncbi request reprint Novel insights in dopamine receptor physiology
    Rosario Pivonello
    Departments of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    Eur J Endocrinol 156:S13-21. 2007
    ..In addition, the recent findings on the relationship between dopamine receptors and neuroendocrine tumors are summarized...
  20. ncbi request reprint Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 67:426-33. 2007
    ..Remission rates of 76, 69.5 and 64.3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2-5 years after cabergoline (CAB) withdrawal...
  21. doi request reprint The growth hormone-insulin-like growth factor axis in glycogen storage disease type 1: evidence of different growth patterns and insulin-like growth factor levels in patients with glycogen storage disease type 1a and 1b
    Daniela Melis
    Department of Pediatrics, Federico II University, Naples, Italy
    J Pediatr 156:663-70.e1. 2010
    ..To investigate the growth hormone (GH)-insulin-like growth factor (IGF) system in patients with glycogen storage disease type 1 (GSD1)...
  22. doi request reprint Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:528-37. 2009
    ..The aim of the study was to investigate the 5-yr impact of surgery and somatostatin analogs (SSA) on glucose metabolism in acromegaly...
  23. ncbi request reprint Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study
    Carolina Di Somma
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University Naples, Italy
    Clin Endocrinol (Oxf) 58:302-8. 2003
    ..Osteoporosis is a frequent, severe and often underestimated consequence of long-term hypercortisolism, often presenting as bone fracture...
  24. ncbi request reprint Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 66:714-22. 2007
    ..Limited data are available on clinical presentation and treatment strategy in patients with GH-secreting adenomas with onset in adolescence...
  25. ncbi request reprint Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Napoli, Italy
    Clin Endocrinol (Oxf) 58:169-76. 2003
    ..Cardiovascular disease is the most frequent cause of death of patients with acromegaly...
  26. doi request reprint Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, Naples, Italy
    J Clin Endocrinol Metab 93:2639-46. 2008
    ..The objective of the study was to investigate whether first-line surgery or somatostatin analogs (SSA) have a different outcome on cardiomyopathy after 12 months...
  27. doi request reprint Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
    Diego Ferone
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:1412-7. 2008
    ..In nine cases, GH and PRL content was further studied by immunoelectron microscopy...
  28. ncbi request reprint Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly
    Annamaria Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 63:342-9. 2005
    ..GH and IGF-I secretion is related to gender and age...
  29. ncbi request reprint Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 65:250-6. 2006
    ....
  30. ncbi request reprint Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Italy
    Eur J Endocrinol 154:467-77. 2006
    ..We aimed to investigate the efficacy of pegvisomant in patients with acromegaly resistant to long-term (> or = 24-month), high-dose treatment with octreotide-LAR (40 mg/month) or lanreotide (120 mg/month)...
  31. ncbi request reprint Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism
    Libuse Tauchmanova
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Eur J Endocrinol 157:359-66. 2007
    ..This study is aimed at investigating the role of sex steroids and severity of hypercortisolism on bone mineral density (BMD) and prevalence of vertebral fractures in female patients...
  32. doi request reprint Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas
    Renata S Auriemma
    Sezione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia, University Federico II, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 169:359-66. 2013
    ..The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia...
  33. ncbi request reprint Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status
    Libuse Tauchmanova
    Department of Molecular, Clinical Endocrinology, and Oncology, Federico II University of Naples, via Sergia Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:1779-84. 2006
    ..e. Cushing's disease and adrenal and ectopic Cushing's syndrome...
  34. ncbi request reprint Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:2112-8. 2006
    ..Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly diagnosed patients with acromegaly...
  35. doi request reprint Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 159:389-97. 2008
    ..In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality...
  36. doi request reprint Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 71:237-45. 2009
    ..To evaluate GH and IGF-I control and tumour shrinkage in newly diagnosed patients with acromegaly treated first-line with lanreotide-Autogel (ATG) 120 mg. Design Open, prospective...
  37. ncbi request reprint Cardiovascular consequences of early-onset growth hormone excess
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:3097-104. 2002
    ..These deleterious effects of early-onset acromegaly are ameliorated by suppressing GH/IGF-I levels for 6 months...
  38. ncbi request reprint Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:85-92. 2006
    ..Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant...
  39. doi request reprint The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission
    Renata S Auriemma
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Via S Pansini 5, Naples, Italy
    Eur J Endocrinol 162:1035-42. 2010
    ..The aim of the study was to investigate renal structure and function in acromegalic patients during active disease and disease remission...
  40. ncbi request reprint The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients
    Annamaria Colao
    Department of Molecular, Clinical Endocrinology and Oncology, Section of Endocrinilogy, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 92:3854-60. 2007
    ..Hyperinsulinemia is associated with colon carcinoma in the general population. Patients with acromegaly are considered to be at risk for developing colonic lesions and typically have hyperinsulinemia...
  41. ncbi request reprint Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 61:360-6. 2004
    ..To investigate the role of IGF-1 on intima-media thickness (IMT) at common carotid arteries by Doppler ultrasonography...
  42. ncbi request reprint Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease
    Antongiulio Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 90:6616-22. 2005
    ..Although a series of cardiovascular risk factors have been identified, sulfur amino acids (SAAs), recently indicated as independent cardiovascular risk factors, have been poorly investigated in patients with Cushing's syndrome...
  43. doi request reprint Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal
    Renata S Auriemma
    Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Eur J Endocrinol 162:993-9. 2010
    ..SA withdrawal has been demonstrated to keep safe levels of GH and IGF1 at least in a small subset of patients well responsive to SA, although it is generally followed by disease recurrence after several months...
  44. ncbi request reprint Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:3746-56. 2009
    ..The objective of the study was to evaluate the efficacy of 5 yr of depot somatostatin analogs (SSAs) as first-line therapy in acromegaly...
  45. doi request reprint Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 93:3777-84. 2008
    ..Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease...
  46. doi request reprint Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation
    Renata S Auriemma
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, I 80131 Napoli, Italy
    J Clin Endocrinol Metab 98:372-9. 2013
    ..The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (CAB)-induced pregnancy and after lactation as well as safety of CAB exposure during early gestation...
  47. ncbi request reprint Hypertension in acromegaly and in the normal population: prevalence and determinants
    Giovanni Vitale
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 63:470-6. 2005
    ..The GH/IGF-I axis has a relevant role to play in the cardiovascular system but its implication in the pathogenesis of hypertension in the normal population and in acromegaly is not yet clear...
  48. doi request reprint Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 74:234-40. 2011
    ..Design  Analytical, retrospective...
  49. doi request reprint Cardiovascular disease in Cushing's syndrome: heart versus vasculature
    Monica De Leo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Neuroendocrinology 92:50-4. 2010
    ....
  50. ncbi request reprint The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 91:2191-200. 2006
    ..Partial GH deficiency (GHD) in adults is poorly studied...
  51. ncbi request reprint Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission
    Antongiulio Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 88:2527-33. 2003
    ..The persistence of a metabolic syndrome, vascular damage, and atherosclerotic plaques after cortisol level normalization makes these subjects still at high cardiovascular risk despite disease remission...
  52. ncbi request reprint Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 156:S57-63. 2007
    ..No data are available in other pituitary tumour histotypes. Preliminary observations in patients with clinically non-functioning adenomas are very promising...
  53. ncbi request reprint Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, Naples, Italy
    J Clin Endocrinol Metab 94:2907-14. 2009
    ..The objective of the study was to investigate the impact of first-line somatostatin analogs (SSAs) on glucose tolerance (GT) in acromegaly...
  54. ncbi request reprint Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    N Engl J Med 349:2023-33. 2003
    ..We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients...
  55. ncbi request reprint The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms
    Maria Teresa Pellecchia
    Department of Neurological Sciences, University of Naples Federico II, Naples, Italy
    Mov Disord 23:190-4. 2008
    ..Our results suggest that the impairment of the central mechanisms modulating GH release differs between PSP and MSA-P...
  56. ncbi request reprint High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80123 Naples, Italy
    J Clin Endocrinol Metab 88:3196-201. 2003
    ....
  57. ncbi request reprint Dopamine receptor agonists for treating prolactinomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 11:787-800. 2002
    ..The great efficacy of this compound together with its excellent tolerability makes this drug the current treatment of choice for the majority of patients with hyperprolactinaemic disorders...
  58. ncbi request reprint Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Via S Pansini 5, Italy
    Eur J Endocrinol 148:325-31. 2003
    ..Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear...
  59. doi request reprint Medical therapy of pituitary adenomas: effects on tumor shrinkage
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Rev Endocr Metab Disord 10:111-23. 2009
    ..NFA respond very scantly to both DA and SSA even if receptors targeting these drugs are present. Whether this is due to limited receptor number or alterations of post-receptor pathway is still unknown...
  60. doi request reprint The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells
    Maria Cristina De Martino
    Division of Endocrinology, Department of Internal Medicine, Room Ee530b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Endocr Relat Cancer 19:351-64. 2012
    ..mTOR could be a target for the treatment of human ACCs, but variable responses might be expected. In selected cases of ACC, the combined targeting of mTOR and IGF2 could have greater effects than mTOR inhibitors alone...
  61. ncbi request reprint Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test
    Maria Teresa Pellecchia
    Department of Neurological Sciences, University of Naples Federico II, Naples, Italy
    Ann Neurol 60:611-5. 2006
    ..Our aim was to evaluate the accuracy of the arginine growth hormone (GH) stimulation test in distinguishing between MSA and PD in large populations of patients...
  62. doi request reprint Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 93:3436-42. 2008
    ..The objective of the study was to evaluate whether tumor shrinkage or GH and IGF-I levels achieved after 3 months predicted tumor shrinkage after 12 months of octreotide-long-acting release (LAR) treatment...
  63. ncbi request reprint First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 64:342-51. 2006
    ..The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor...
  64. ncbi request reprint Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly
    Annamaria Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 157:579-87. 2007
    ..To evaluate the efficacy of dose escalation of Octreotide-long-acting repeatable (LAR) up to 40 mg/month we studied 56 newly diagnosed patients with acromegaly (24 women, 32 men; age 20-82 years)...
  65. ncbi request reprint Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 90:2056-62. 2005
    ..These findings support the indication for GH replacement in severe GH deficiency adult patients...
  66. doi request reprint GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 69:613-20. 2008
    ..Approximately one-third of patients with acromegaly have concomitant hypertension. The outcome of hypertension after treatment of acromegaly is unknown...
  67. pmc Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease
    Maria Teresa Pellecchia
    Department of Neurological Sciences, University Federico II, Via Pansini 5, 80131 Naples, Italy
    Clin Med Res 4:322-5. 2006
    ..This review summarizes the results of several studies and discusses the validity of these tests in the differential diagnosis of parkinsonisms...
  68. ncbi request reprint Acromegaly and the cardiovascular system
    Gaetano Lombardi
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Neuroendocrinology 83:211-7. 2006
    ..In conclusion, an early diagnosis and a careful evaluation of cardiac function, morphology and activity seem to be mandatory in acromegaly...
  69. ncbi request reprint Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University Naples, Italy
    Clin Endocrinol (Oxf) 52:319-27. 2000
    ..To evaluate the effect of hyperprolactinaemia and its treatment with dopamine-agonists on bone mass and turnover in adolescent patients compared to adults...
  70. ncbi request reprint Somatostatin analogues: treatment of pituitary and neuroendocrine tumors
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Prog Brain Res 182:281-94. 2010
    ..A recent study has also demonstrated a beneficial effect of OCT long-acting release in patients with non-functioning NETs independently from their progression status. These data open the treatment with SSAs in all NET patients...
  71. ncbi request reprint The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:1088-93. 2002
    ..A similar period of GH deprivation induced a further impairment of lipid profile and cardiac performance. This finding strongly supports the need of GH replacement in adult GHD patients...
  72. ncbi request reprint Medical consequences of acromegaly: what are the effects of biochemical control?
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131, Naples, Italy
    Rev Endocr Metab Disord 9:21-31. 2008
    ....
  73. ncbi request reprint The treatment algorithm of acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:39-45. 2003
  74. doi request reprint Medical therapy for clinically non-functioning pituitary adenomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy
    Endocr Relat Cancer 15:905-15. 2008
    ..Lack of randomized, placebo-controlled trials prevents any conclusion on the efficacy of these drugs. By contrast, use of gonatotrophin-releasing hormone analogues has been abandoned...
  75. ncbi request reprint Antipituitary antibodies in idiopathic hyperprolactinemic patients
    Annamaria De Bellis
    Department of Clinical and Experimental Medicine and Surgery, F Magrassi, A Lanzara, Second University of Naples, Naples, Italy
    Ann N Y Acad Sci 1107:129-35. 2007
    ..A future longitudinal study of these patients submitted to cabergoline therapy or free of therapy may be helpful to clarify this assumption...
  76. ncbi request reprint Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma
    Daniele Mattera
    Department of Clinical and Experimental Medicine, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 59:699-706. 2003
    ..The development of hepatocellular carcinoma in liver cirrhosis is associated with altered synthesis and secretion of several growth factors...
  77. ncbi request reprint Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure
    Antongiulio Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 88:2076-80. 2003
    ....
  78. ncbi request reprint Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Endocrine 20:279-83. 2003
    ..No evident effect of tumor shrinkage has been reported. At present, the use of somatostatin analogs in clinically nonfunctioning adenomas is questioned...
  79. ncbi request reprint Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study
    S Grottoli
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    J Endocrinol Invest 28:978-83. 2005
    ..Octreotide LAR could be used as primary therapy in patients harbouring large pituitary tumors, who are less likely to be cured by neurosurgery...
  80. ncbi request reprint The role of somatostatin analogs in the management of hepatocellular carcinoma
    L D'Agostino
    Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
    J Endocrinol Invest 26:131-3. 2003
  81. ncbi request reprint New perspectives in the medical treatment of acromegaly
    A Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Endocrinol Invest 28:58-66. 2005
    ..These drugs have been also shown to possess strong GH-inhibitory activity in primary cultures from GH-secreting adenomas. These drugs are the future perspectives in the treatment of patients with GH-secreting or GH/PRL-secreting tumors...
  82. ncbi request reprint Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs
    C Matrone
    Division of Pharmacology, Department of Neuroscience, Federico II University, Naples, Italy
    Neuroendocrinology 79:142-8. 2004
    ....
  83. ncbi request reprint Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly
    A Colao
    Department of Molecular, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:4193-7. 2002
    ..45; P = 0.006). In conclusion, short-term GH and IGF-I suppression after surgery or LAN significantly increased T and DHT levels and improved sperm number and motility in acromegalic men...
  84. ncbi request reprint In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy
    D Ferone
    Department of Molecular and Clinical Endocrinology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 54:469-77. 2001
    ..The new potent DA might be primarily considered in the medical treatment of hyperprolactinemic acromegalics, while SA alone or in combination with DA in case of ineffective hormone suppression...
  85. ncbi request reprint Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 84:1919-24. 1999
    ..These abnormalities were consistently present in all patients with GHD regardless of the presence of additional hormone deficits, suggesting that GHD plays a central role in the development of osteopenia in hypopituitary patients...
  86. ncbi request reprint Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure
    A Colao
    Department of Molecular and Clinical Endocrinology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 84:2664-72. 1999
    ....
  87. ncbi request reprint SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas
    Monica Fedele
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR e o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 13:2738-44. 2007
    ..This animal model has been used to evaluate the therapeutic efficacy of SOM230, a somatostatin analogue with high affinity for the somatostatin receptor subtypes 1, 2, 3, and 5, on the growth of the pituitary adenomas...
  88. ncbi request reprint Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease
    A Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Pituitary 4:187-93. 2001
    ....
  89. ncbi request reprint Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study
    R S Auriemma
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, 80131 Naples, Italy
    J Endocrinol Invest 31:956-65. 2008
    ..Therefore, both drugs can be safely employed as first-line therapy of acromegaly...
  90. ncbi request reprint Spine abnormalities and damage in patients cured from Cushing's disease
    A Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Pituitary 4:153-61. 2001
    ..Therefore, a periodical radiological follow-up of the skeleton and a specific treatment for the bone damage should be included in the management of patients with Cushing's syndrome...
  91. ncbi request reprint Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 52:447-55. 2000
    ..Long-standing GH deficiency (GHD) causes several abnormalities in cardiac structure and performance which ultimately determine an increased cardiovascular morbidity and mortality...
  92. ncbi request reprint Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease
    A Faggiano
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Endocrinol Invest 25:142-51. 2002
    ..Normalization of cortisol levels restored the amino acid profile...
  93. ncbi request reprint Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 54:515-24. 2001
    ..Despite the increasing evidence for the existence of a specific cardiomyopathy in acromegaly, the presence of vascular abnormalities has been never investigated...
  94. ncbi request reprint Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome
    L Tauchmanova
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    J Endocrinol Invest 32:390-4. 2009
    ..Currently, it is unclear if patients with subclinical Cushing's syndrome (SCS) with osteoporosis or osteopenia may benefit from antiresorptive treatment and the type of therapy to be given...
  95. ncbi request reprint Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
    A Colao
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 85:2247-52. 2000
    ..In conclusion, the prevalence of macroprolactinoma shrinkage after CAB treatment at standard doses for 1-3 yr was higher in naive patients (92.3%) than in intolerant (42.1%), resistant (30.3%), and responsive patients (38.4%). Thus, C..
  96. doi request reprint Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency
    C Di Somma
    IRCCS SDN Foundation, Naples, Italy
    J Endocrinol Invest 33:171-7. 2010
    ....
  97. ncbi request reprint Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients
    A Colao
    Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Eur J Endocrinol 143:61-9. 2000
    ..The role of IGF-I in prostate development is currently under thorough investigation since it has been claimed that IGF-I is a positive predictor of prostate cancer...
  98. ncbi request reprint Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 53:13-9. 2000
    ..Cushing's disease is characterized by abnormalities of immune function...
  99. ncbi request reprint Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy
    A Di Sarno
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, 80131 Naples, Italy
    J Clin Endocrinol Metab 86:5256-61. 2001
    ..Therefore, an absence of tumor shrinkage cannot be considered as end point to indicate resistance to CAB, and increasing the dose of CAB higher than 3 mg/wk does not seem to be helpful in controlling PRL hypersecretion...
  100. ncbi request reprint Pegvisomant in acromegaly: why, when, how
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
    J Endocrinol Invest 30:693-9. 2007